We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add NVST Stock to Your Portfolio Right Now
Read MoreHide Full Article
Key Takeaways
NVST is expanding internationally, with emerging-market sales rising nearly 238% in Q3 of 2025.
NVST is pursuing bolt-on acquisitions, adding Osteogenics and Carestream's scanner business.
NVST ended Q3 2025 with $1.13B cash, no current debt, and net debt near 1X adjusted EBITDA.
Envista Holdings Corporation’s (NVST - Free Report) international expansion positions it for robust future growth due to deeper penetration across more markets. Additionally, it continuously assesses potential buys that either strategically complement its current portfolio or broaden it into new and lucrative economic sectors. Meanwhile, a strong solvency bodes well. Yet, currency fluctuations raise concerns for Envista’s operations.
In the past year, this Zacks Rank #2 (Buy) stock has gained 19.1%, outpacing the industry’s decline of 3.9%. The S&P 500 composite grew 19% in the same time frame.
The leading optical retailer has a market capitalization of $3.71 billion. The company’s earnings yield of 5.6% is well ahead of the industry’s 2.5%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.80%.
Tailwinds for NVST
Focus on International Market Expansion: Outside the United States, Envista has principal markets in Europe, Asia, the Middle East and Latin America. The company continues to expand clinical training and education infrastructure to enhance patient access to high-quality dental care, reaching over 250,000 dental professionals annually. Through its trusted brands, innovative product offerings and comprehensive customer service, it has established strong relationships globally with key constituencies, including DSOs, dental specialists, general dentists and dental laboratories.
We believe that this increasing penetration across geographies positions Envista well for substantial future growth. With respect to emerging markets, which the company defines as developing regions experiencing extended periods of accelerated growth in gross domestic product and infrastructure, sales increased nearly 238% in the third quarter of 2025.
Strategic Acquisitions to Drive Growth: Envista's growth strategy contemplates future acquisitions, and it continuously assesses potential buys that either strategically complement its current portfolio or broaden it into new and lucrative economic sectors. In the first half of 2025, the company closed two small acquisitions, both at favourable EBITDA multiples to support its ongoing organic initiatives.
The 2022 acquisition of Osteogenics added innovative regenerative solutions that are highly complementary to the implant treatment. Envista also acquired Carestream’s Intraoral Scanner business, integrating intraoral scanners and related software into the Imaging portfolio. It now operates as DEXIS under the company’s Equipment and Consumables segment.
Favorable Solvency: At the end of the third quarter of 2025, the company had cash and cash equivalents of $1.13 billion, while current debt was nil. Such underlying financial strength gives Envista strong flexibility amid the ongoing macroeconomic uncertainty.
Image Source: Zacks Investment Research
Long-term debt of $1.45 billion remained consistent with the second-quarter levels. The company’s net debt to adjusted EBITDA was approximately 1X, signaling stability and flexibility, particularly during periods of heightened macroeconomic uncertainty. Meanwhile, times interest earned jumped 1.4% from the second quarter to 5.3X.
Concern for NVST
Foreign Exchange Impacting Sales: Significant portions of Envista's sales and costs are exposed to changes in foreign exchange rates. The company’s operations use multiple foreign currencies, including the euro, British pound, Brazilian real, Australian dollar, Japanese yen, Canadian dollar and Chinese yuan.
Changes in those currencies relative to the U.S. dollar will impact its sales, cost of sales and expenses, and consequently, net income. In the second quarter of 2025, Envista’s operating profit was partially offset by higher costs due to the impact of unfavorable foreign exchange rates.
NVST Stock Estimate Trend
The Zacks Consensus Estimate for 2025 earnings per share (EPS) has remained unchanged at $1.14 in the past 30 days.
The Zacks Consensus Estimate for 2025 revenues is pegged at $2.64 billion, suggesting a 5.3% increase from the year-ago reported number.
Other Top MedTech Stocks
Some other top-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) , BrightSpring Health Services (BTSG - Free Report) and Quest Diagnostics (DGX - Free Report) .
Phibro Animal Healthhas an earnings yield of 7.4% compared with the industry’s 0.2% yield. Shares of the company have surged 86.2% in the past year against the industry’s 5% decline. PAHC’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 20.8%.
BrightSpring Health Services, currently carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 53.3% compared with the industry’s 15.5% growth. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 45.1%. BTSG shares have surged 130.2% compared with the industry’s 5.2% growth in the past year.
Quest Diagnostics, carrying a Zacks Rank #2 at present, has an earnings yield of 5.6% compared with the industry’s 5% yield. Shares of the company have jumped 13.9% compared with the industry’s 5.2% growth. DGX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 2.5%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why You Should Add NVST Stock to Your Portfolio Right Now
Key Takeaways
Envista Holdings Corporation’s (NVST - Free Report) international expansion positions it for robust future growth due to deeper penetration across more markets. Additionally, it continuously assesses potential buys that either strategically complement its current portfolio or broaden it into new and lucrative economic sectors. Meanwhile, a strong solvency bodes well. Yet, currency fluctuations raise concerns for Envista’s operations.
In the past year, this Zacks Rank #2 (Buy) stock has gained 19.1%, outpacing the industry’s decline of 3.9%. The S&P 500 composite grew 19% in the same time frame.
The leading optical retailer has a market capitalization of $3.71 billion. The company’s earnings yield of 5.6% is well ahead of the industry’s 2.5%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.80%.
Tailwinds for NVST
Focus on International Market Expansion: Outside the United States, Envista has principal markets in Europe, Asia, the Middle East and Latin America. The company continues to expand clinical training and education infrastructure to enhance patient access to high-quality dental care, reaching over 250,000 dental professionals annually. Through its trusted brands, innovative product offerings and comprehensive customer service, it has established strong relationships globally with key constituencies, including DSOs, dental specialists, general dentists and dental laboratories.
We believe that this increasing penetration across geographies positions Envista well for substantial future growth. With respect to emerging markets, which the company defines as developing regions experiencing extended periods of accelerated growth in gross domestic product and infrastructure, sales increased nearly 238% in the third quarter of 2025.
Strategic Acquisitions to Drive Growth: Envista's growth strategy contemplates future acquisitions, and it continuously assesses potential buys that either strategically complement its current portfolio or broaden it into new and lucrative economic sectors. In the first half of 2025, the company closed two small acquisitions, both at favourable EBITDA multiples to support its ongoing organic initiatives.
The 2022 acquisition of Osteogenics added innovative regenerative solutions that are highly complementary to the implant treatment. Envista also acquired Carestream’s Intraoral Scanner business, integrating intraoral scanners and related software into the Imaging portfolio. It now operates as DEXIS under the company’s Equipment and Consumables segment.
Favorable Solvency: At the end of the third quarter of 2025, the company had cash and cash equivalents of $1.13 billion, while current debt was nil. Such underlying financial strength gives Envista strong flexibility amid the ongoing macroeconomic uncertainty.
Image Source: Zacks Investment Research
Long-term debt of $1.45 billion remained consistent with the second-quarter levels. The company’s net debt to adjusted EBITDA was approximately 1X, signaling stability and flexibility, particularly during periods of heightened macroeconomic uncertainty. Meanwhile, times interest earned jumped 1.4% from the second quarter to 5.3X.
Concern for NVST
Foreign Exchange Impacting Sales: Significant portions of Envista's sales and costs are exposed to changes in foreign exchange rates. The company’s operations use multiple foreign currencies, including the euro, British pound, Brazilian real, Australian dollar, Japanese yen, Canadian dollar and Chinese yuan.
Changes in those currencies relative to the U.S. dollar will impact its sales, cost of sales and expenses, and consequently, net income. In the second quarter of 2025, Envista’s operating profit was partially offset by higher costs due to the impact of unfavorable foreign exchange rates.
NVST Stock Estimate Trend
The Zacks Consensus Estimate for 2025 earnings per share (EPS) has remained unchanged at $1.14 in the past 30 days.
The Zacks Consensus Estimate for 2025 revenues is pegged at $2.64 billion, suggesting a 5.3% increase from the year-ago reported number.
Other Top MedTech Stocks
Some other top-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) , BrightSpring Health Services (BTSG - Free Report) and Quest Diagnostics (DGX - Free Report) .
Phibro Animal Healthhas an earnings yield of 7.4% compared with the industry’s 0.2% yield. Shares of the company have surged 86.2% in the past year against the industry’s 5% decline. PAHC’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 20.8%.
PAHC sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
BrightSpring Health Services, currently carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 53.3% compared with the industry’s 15.5% growth. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 45.1%. BTSG shares have surged 130.2% compared with the industry’s 5.2% growth in the past year.
Quest Diagnostics, carrying a Zacks Rank #2 at present, has an earnings yield of 5.6% compared with the industry’s 5% yield. Shares of the company have jumped 13.9% compared with the industry’s 5.2% growth. DGX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 2.5%.